HOLD. Entry at $240 not current levels ($257). Trim 10-15% above $260 resistance. Reject any adds above $250 until MACD confirmation above signal line and clean close above $260.

• Stock extended +13.6% above 200 SMA—historically mediocre forward 3-month returns for stocks at double-digit premiums to 200-day MA
• ABBV at 96% of its 52-week high leaves no room for multiple expansion; requires moving from forward P/E 15.8x to 18-20x on a $454 billion market cap
• Skyrizi and Rinvoq at 33% of revenue and 60-70% of growth narrative creates structural concentration vulnerability
• MACD bearish crossover still in effect; histogram compression can resolve in either direction and may expand violently on Q3 earnings miss
• Q3 earnings asymmetry is to the downside—upside to $270-275 (7%) vs downside to $240-245 (5-7%) is roughly symmetric, not asymmetric to upside
• Defensive rotation into ABBV has already occurred (up 25% YTD); pension and insurance fund rotation largely exhausted
• $67.5B in total debt post-Apogee with integration risk, rating agency reaction, and leverage trajectory unknown—Apogee closed only 8 days ago
• Imbruvica LOE in 2027 plus competitive threats from LLY immunology buildout and MLTX biosimilar collapse suggest category more competitive than assumed
• Trimming 10-15% at resistance is prudent portfolio management, not 'leaving money on the table'—locks in gains after 25% YTD run with concentration risk

→ vs aggressive: Momentum-chasing error: claiming 'trend's prime' from 200 SMA slope is lagging-indicator reasoning; extended moves are most vulnerable to mean reversion precisely because they're extended

→ vs aggressive: 3.4% bounce in 3 days after 9/8 dip is not 'accumulation'—it replenishes overhead supply by giving underwater sellers a second exit opportunity

→ vs aggressive: Phase 3 wins already acknowledged by market at 96% of 52-week high; multiple expansion thesis requires consensus to be wrong, low-probability bet for mega-cap pharma

→ vs aggressive: Information asymmetry claim is wrong—market has already updated models; asymmetry now favors downside on any Q3 miss, not upside

→ vs aggressive: Defensive rotation timing error: ABBV up 25% YTD means rotation already exhausted, not at front door; forward expected return substantially lower post-rotation

→ vs neutral: Wait-and-see framing creates illusion of action without risk reduction; should actively trim into $260 strength, not as afterthought—trim is risk management, not leaving money on table

HOLD with refined tactical framework: Hold core position, lower add zone to $250-$254 from $250-$257, require MACD confirmation or close above $258.25 Bollinger mid-band before adding, replace part of trim with collar/covered call overlay into Q3, trim 5-10% above $260 (softer than Conservative's 10-15%), ATR-based sizing at $5.74/share.

• HOLD is correct final position; trader's framework is sound but needs refinement
• Aggressive analyst correctly identifies catalyst density (three Phase 3 wins, $10.9B acquisition) and Qulipta menstrual migraine TAM expansion with no on-label competition
• Aggressive analyst's position breaks down at 96% of 52-week high with $67.5B debt load on balance sheet for 8 days; risk-reward is symmetric or skewed to downside
• Conservative analyst correctly identifies concentration risk (Skyrizi + Rinvoq at ~1/3 revenue and 60-70% of growth narrative) and $67.5B debt post-Apogee as structural vulnerabilities
• Q3 risk-reward math is approximately symmetric: upside ~7% to $270-$275 on beat, downside 5-7% to $240-$245 on miss, making it a coin flip at current levels
• Replace straight trim with collar or covered call overlay to preserve upside while managing event risk
• Add zone reduced from $250-$257 to $250-$254 with conditional confirmation triggers
• Entry zone of $240 with stop at $247 provides 7% downside buffer at Bollinger lower band
• ATR-based risk management at $5.74/share is volatility-adjusted and sound
• Hawkish Fed regime is not fully crystallized despite Polymarket pricing 90% odds of hike; 10-year yield holding below 5% suggests uncertainty
• Polymarket moved 18 percentage points in one week on hike probability, indicating regime is still developing

→ vs aggressive: Adding at current levels (96% of 52-week high) with $67.5B debt load is not asymmetric upside; the stock has already captured most of the news flow from Phase 3 wins and acquisition

→ vs aggressive: The 'coiled spring zone' framing at $250-$257 is analysis paralysis inverted; waiting for confirmation exists precisely because cost of being wrong is asymmetric at current levels

→ vs conservative: Critiquing the 200 SMA slope as lagging is fair but overcorrecting; steepening 200 SMA combined with 50 SMA holding on 9/8 test is a meaningful signal, not a coincidence

→ vs conservative: 25% YTD move reflects Skyrizi/Rinvoq execution and Humira replacement narrative; hawkish regime rotation is incremental layer, not the same driver, so rotation exhaustion argument is backwards logic